Myositis

#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2023
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush @RheumNow( View Tweet )

Jun 01, 2023
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush @RheumNow( View Tweet )
Jun 01, 2023
Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh
Dr. John Cush @RheumNow( View Tweet )
Jun 01, 2023
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG). https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB

Links:

Dr. John Cush @RheumNow( View Tweet )
May 15, 2023
Clot.DVT_.VTE_.blood_.jpg

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

Jack Cush, MD
May 11, 2023

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).



Previous studies have shown an increased risk of VTE in DM patients, usually within 2 years of onset. Moreover, the FDA has recently

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Jack Cush, MD
Apr 14, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.




  1. 2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271

Read Article
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je

Links:

Dr. John Cush @RheumNow( View Tweet )
Apr 13, 2023
NEJM Clinical image: 61-year-old woman presented with a 6-month history of periorbital swelling and shoulder weakness. The physical examination was notable for erythema of the upper and lower eyelids and substantial periorbital edema. Dermatomyositis. https://t.co/1Vu1Lh37Hd https://t.co/Bh7FXDgMRx

Links:

Dr. John Cush @RheumNow( View Tweet )
Apr 11, 2023
Ccancer detection study in idiopathic inflammatory myositis: found w/in 3 yrs of onset 9/1011 (0.9%) CT chest & 12/657(1.8%) CT Dx cancer. Yield best w/ DM, TIF1γ pos. Yield very low age<40 yrs; high false(+) w/ antisynthetase synd & necrotizing myositis https://t.co/FCBwEYW1eT https://t.co/DAEj83xmam

Links:

Dr. John Cush @RheumNow( View Tweet )
Mar 15, 2023
RheumNow Podcast square

Big Time Vasculitis (3.10.2023)

Jack Cush, MD
Mar 10, 2023

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?




Read Article
myositis.jpg

Long-Term Survival of Idiopathic Inflammatory Myopathies

Jack Cush, MD
Mar 09, 2023

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.



This was a retrospective single-centre analysis of IIM patients

Read Article
Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/DlKs3DGWNu https://t.co/M7qrcfcE2y

Links:

Dr. John Cush @RheumNow( View Tweet )
Mar 06, 2023
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

Jack Cush, MD
Mar 03, 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.




  1. Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have

Read Article
Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, brucellosis, syphilis, PBC, RA, systemic sclerosis , lymphoma, checkpoint inhibitors, GVHD, natural killer/T-cell lymphoma https://t.co/5IUaC1ln7G https://t.co/guYtvyaaHU

Links:

Dr. John Cush @RheumNow( View Tweet )
Feb 20, 2023
RheumNow Podcast square

Burnout #10 (2.3.2023)

Jack Cush, MD
Feb 03, 2023

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Read Article
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku

Links:

Dr. John Cush @RheumNow( View Tweet )
Feb 01, 2023
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

Jack Cush, MD
Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.




  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article
Lungs ILD

Best of 2022: Approach to ILD in Myositis Syndromes

Jack Cush, MD
Dec 19, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article
Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/h6zpTOIuyu https://t.co/Gy3Eaqz8sM

Links:

Dr. John Cush @RheumNow( View Tweet )
Dec 12, 2022
infusion.biologic.jpg

RECITAL Trial: RTX vs. CTX in CTD-ILD

Jack Cush, MD
Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW

Links:

Dr. Rachel Tate @uptoTate( View Tweet )
Nov 13, 2022
Very important point about statin induced myopathy by Dr. Christopher-Stine. If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy! @RheumNow #ACR22 https://t.co/VHxPRkCWwj
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 12, 2022
What if my #myositis patient gets pregnant? Abstract #0952 #ACR22 @RheumNow 🫁10 pregnancies ➡️ 1 miscarriage -2 preterm -3 low birth wght -1 HELLP -Mean gestational age 36w 🫁 Higher disease activity ➡️ more adverse pregnancy outcomes

Catherine Sims, MD @DrCassySims( View Tweet )

Nov 12, 2022
Key points in managing MDA5+ DM 1. Monitor lungs - HRCT/PFTs 2. Test muscle endurance (ref: IMACS site) not just strength 3. Close observation 4. MTX/MMF initial treatments 5. Repeat muscle biopsy if diagnosis unclear Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 12, 2022

Recent Blogs

A Winning Season*

Jack Cush, MD
Sep 09, 2015
football.jpg

Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.

Read Post

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×